Targeting chromosomal chaos Accent Therapeutics advances a KIF18A inhibitor, leveraging genomic instability to create druggable dependencies.

https://www.drugdiscoverynews.com/targeting-chromosomal-chaos-17128 At the 2026 international conference of the Society for Laboratory Automation and Screening (SLAS), Serena Silver, Chief Scientific Officer of Accent Therapeutics, laid out a precision oncology strategy built around a structural feature of cancer genomes rather than a single mutated gene.